Investment case
Labcorp
LH · 6 developments mapped · last assessed 2026-09-11
Market Ontology has mapped 6 macro, policy, and market developments to Labcorp since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for LH yet, so no modelled value is shown. The LH valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run LH on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
Increased competition in the early-phase clinical research market from a strengthened Fortrea, potentially impacting market share or pricing power.
· Moves market share in clinical research services, pricing power in early phase trials
What changed, by assumption
- 2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
- 2026-09-11GMR Solutions Inc. Secures Commitments for $2.9 Billion Term Loan Repricing and $200 Million Debt Paydown
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-11 | GMR Solutions Inc. Secures Commitments for $2.9 Billion Term Loan Repricing and $200 Million Debt Paydown | watch | 3-12m | 0.20 |
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M | watch | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M | watch | 3-12m | 0.30 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M | mixed | 3-12m | 0.30 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million | mixed | 3-12m | 0.30 |
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million | mixed | 3-12m | 0.30 |